Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > September expectations

<< Previous

Bullboard Posts

Next >>

Comment by LouisWon Aug 16, 2022 12:45am

150 Views

Post# 34898415

RE:RE:RE:September expectations

Paul mentioned on the Q2 finacial meeting that they will probably announced the result in the second half of the year. From my point of view, the perfect time to announce the result is few days before the Q3 financial meeting and they can discuss it on the meeting.. I think that we will be hearing a bunch of PR from from early Oct to mid Oct.

Besides, the fact that two largest shareholders, Soleus and Morgan Stanley are significantly accumulating the shares which gives me the confidence not selling the share.

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment